<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04845880</url>
  </required_header>
  <id_info>
    <org_study_id>KA20/449</org_study_id>
    <nct_id>NCT04845880</nct_id>
  </id_info>
  <brief_title>SARS Cov_2 Incidence of Healthy Health Workers</brief_title>
  <official_title>Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 Patients in Our Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baskent University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hikmet Eda Aliskan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hatice Hale Gumus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ilker Odemis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuhal Ekici Unsal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baskent University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since the severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2) first emerged in&#xD;
      Wuhan, China, on 12 December 2019, it has spread rapidly across the world and developed into&#xD;
      a pandemic. The pandemic has affected over 100 countries and regions, with over 132 million&#xD;
      confirmed cases of COVID-19. The rapid spread of SARS-CoV-2 has caused considerable harm to&#xD;
      public health and the economy. Alongside other laboratory tests and clinical findings of the&#xD;
      COVID-19 infection, serological testing may be beneficial for epidemiological monitoring and&#xD;
      outbreak control. The determination of antibodies enables confirmation of the SARS-CoV-2&#xD;
      infection in asymptomatic patients in addition to those with typical symptoms. In this study,&#xD;
      we aimed to determine the SARS-CoV-2 seroprevalence and the IgG antibody levels among&#xD;
      healthcare workers who frequently encountered COVID-19 patients in our hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Actual">April 1, 2021</completion_date>
  <primary_completion_date type="Actual">March 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of IgG Neutralizing Antibodies to SARS-CoV-2 Among Healthcare Workers Who Frequently Encountered COVID-19 patients in Our Hospital</measure>
    <time_frame>6 months</time_frame>
    <description>Determining antibody levels and seroprevalence of healthy healthcare workers</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">182</enrollment>
  <condition>SARS COV-2 IgG Levels on Health Workers</condition>
  <arm_group>
    <arm_group_label>SARS Cov_2 Incidence of Healthy Health Workers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Spike protein (S) or the nucleocapsid (N) of SARS-CoV-2</intervention_name>
    <description>Blood level of spike protein (S) or the nucleocapsid (N) of SARS-CoV-2</description>
    <arm_group_label>SARS Cov_2 Incidence of Healthy Health Workers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Health Workers - SARS COV-2 PCR (-)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Health Workers - SARS COV-2 PCR (+) Pregnancy Autoimmune diseases Received&#xD;
        immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Adana Dr. Turgut Noyan Application and Research Center</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J, Yan F. Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect. 2020 Apr;80(4):388-393. doi: 10.1016/j.jinf.2020.02.016. Epub 2020 Feb 26.</citation>
    <PMID>32112884</PMID>
  </reference>
  <reference>
    <citation>Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, Xing F, Liu J, Yip CC, Poon RW, Tsoi HW, Lo SK, Chan KH, Poon VK, Chan WM, Ip JD, Cai JP, Cheng VC, Chen H, Hui CK, Yuen KY. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020 Feb 15;395(10223):514-523. doi: 10.1016/S0140-6736(20)30154-9. Epub 2020 Jan 24.</citation>
    <PMID>31986261</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>April 13, 2021</last_update_submitted>
  <last_update_submitted_qc>April 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baskent University</investigator_affiliation>
    <investigator_full_name>Hasan Yesilagac</investigator_full_name>
    <investigator_title>Specialist Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myeloma Proteins</mesh_term>
    <mesh_term>Paraproteins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

